



Journal Articles

2019

Erratum: This article corrects: Best practices for evaluation and treatment of agitated children and adolescents (Beta) in the emergency department: Consensus statement of the American Association for Emergency psychiatry (Western Journal of Emergency Medicine (2019) 20: 2 (409-419) DOI: 10.5811/westjem.2019.1.41344)

R. Gerson

N. Malas

V. Feuer

Zucker School of Medicine at Hofstra/Northwell, vfeuer@northwell.edu

G. H. Silver

R. Prasad

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/articles>



Part of the [Psychiatry Commons](#)
See next page for additional authors

Recommended Citation

Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Erratum: This article corrects: Best practices for evaluation and treatment of agitated children and adolescents (Beta) in the emergency department: Consensus statement of the American Association for Emergency psychiatry (Western Journal of Emergency Medicine (2019) 20: 2 (409-419) DOI: 10.5811/westjem.2019.1.41344). . 2019 Jan 01; 20(4):Article 5781 [p.]. Available from: <https://academicworks.medicine.hofstra.edu/articles/5781>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors

R. Gerson, N. Malas, V. Feuer, G. H. Silver, R. Prasad, and M. M. Mroczkowski

This Article Corrects: “Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the Emergency Department: Consensus Statement of the American Association for Emergency Psychiatry”

Ruth Gerson, MD*
Nasuh Malas, MD, MPH†
Vera Feuer, MD‡
Gabrielle H. Silver, MD§
Raghuram Prasad, MD¶
Megan M. Mroczkowski, MD||

*Bellevue Hospital/New York University, Department of Psychiatry, New York, New York
†University of Michigan, Departments of Psychiatry and Pediatrics, Ann Arbor, Michigan
‡Northwell Health, Department of Psychiatry, New Hyde Park, New York
§Weill Cornell Medical College, Department of Psychiatry, New York, New York
¶Children's Hospital of Philadelphia, Department of Psychiatry, Philadelphia, Pennsylvania
||Columbia University Medical Center, Department of Psychiatry, New York, New York

Electronically published July 2, 2019

Full text available through open access at http://escholarship.org/uc/uciem_westjem

DOI: 10.5811/westjem.2019.4.44160

West J Emerg Med. 2019 March;20(2):409-419

Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the Emergency Department: Consensus Statement of the American Association for Emergency Psychiatry
Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM

Erratum in

West J Emerg Med. 2019 July;20(4):688-689. There was a dosing error in Table 2 regarding haloperidol dosing in pediatric agitation. The dose is listed as 0.55 mg/kg/dose and should be corrected to 0.05-0.1 mg/kg/dose.

Abstract

Introduction: Agitation in children and adolescents in the emergency department (ED) can be dangerous and distressing for patients, family and staff. We present consensus guidelines for management of agitation among pediatric patients in the ED, including non-pharmacologic methods and the use of immediate and as-needed medications.

Methods: Using the Delphi method of consensus, a workgroup comprised of 17 experts in emergency child and adolescent psychiatry and psychopharmacology from the the American Association for Emergency Psychiatry and the American Academy of Child and Adolescent Psychiatry Emergency Child Psychiatry Committee sought to create consensus guidelines for the management of acute agitation in children and adolescents in the ED.

Results: Consensus found that there should be a multimodal approach to managing agitation in the ED, and that etiology of agitation should drive choice of treatment. We describe general and specific recommendations for medication use.

Conclusion: These guidelines describing child and adolescent psychiatry expert consensus for the management of agitation in the ED may be of use to pediatricians and emergency physicians who are without immediate access to psychiatry consultation.

PMCID: PMC6404720 [PubMed - indexed for MEDLINE]

Table 2. Medication reference.

Medication	Dose	Peak effect	Max daily dose	Notes/monitoring
Diphenhydramine (antihistaminic)	PO/IM: 12.5-50mg 1 mg/kg/dose	PO: 2 hours	Child: 50-100 mg Adolescent: 100-200 mg	Avoid in delirium. Can be combined with haloperidol or chlorpromazine if concerns for EPS. Can cause disinhibition or delirium in younger or DD youth.
Lorazepam (benzodiazepine)	PO/IM/IV/NGT: 0.5 mg-2 mg 0.05 mg-0.1 mg/kg/dose	IV: 10 minutes PO/IM: 1-2 hours	Child: 4 mg Adolescent: 6-8 mg Depending on weight/proir medication exposure	Can cause disinhibition or delirium in younger or DD youth. Can be given with haloperidol, chlorpromazine or risperidone. Do not give with olanzapine (especially IM due to risk of respiratory suppression.
Clonidine (alpha2 agonist)	PO: 0.05 mg-0.1 mg	PO: 30-60 minutes	27-40.5 kg: 0.2 mg/day 40.5-45 kg: 0.3 mg/day >45 kg: 0.4mg/day	Monitor for hypotension and bradycardia. Avaoid giving with BZD or atypicals due to hypotension risk.
Chlorpromazine (antipsychotic)	PO/IM: 12.5-60 mg (IM should be half PO dose) 0.55 mg/kg/dose	PO: 30-60 minutes IM: 15 minutes	Child <5 years: 40mg/day Child >5 years: 75mg/day	Monitor hypotension. Monitor for QT prolongation.
Haloperidol (antipsychotic)	PO/IM: 0.5 mg-5 mg (IM should be half a dose of PO) 0.05-0.1 mg/kg/dose	PO: 2 hours IM: 20 minutes	15-40 kg: 6mg >40 kg: 15 mg Depending on prior antipsychotic exposure	Monitor hypotension. Consider EKG or cardiac monitoring for QT prolongation, especially for IV administration. Note EPS risk with MDD > 3mg/day, with IV dosing having very high EPS risk. Consider AIMS testing.
Olanzapine (antipsychotic)	PO/ODT or IM: 2.5-10 mg (IM should be half or 1/4 dose of PO)	PO: 5 hours (range 1-8 hours) IM: 15-45 minutes	10-20 mg Depending on antipsychotic exposure	Do not give with or within 1 hour of any BZD given risk for respiratory suppression
Risperidone (antipsychotic)	PO/ODT: 0.25-1mg 0.005-0.01mg/kg/dose	PO: 1 hour	Child: 1-2 mg Adolescent: 2-3 mg Depending on antipsychotic exposure	Can cause akathisia (restlessness/agitaion) in higher doses.
Quetiapine (antipsychotic)	PO: 25-50 mg 1-1.5 mg/kg/dose (or divided)	PO: 30 minutes-2 hours	>10 years: 600 mg Depending on prior antipsychotic exposure	More sedating at lower doses Monitor hypotension.

PO, by mouth; IM, intramuscular; IV, intravenous; NGT, nasogastric tube; mg, milligram; EPS, extrapyramidal symptoms; DD, developmental disability; mg/kg, milligrams per kilogram; BZD, benzodiazepines; EKG, electrocardiogram; AIMS, Abnormal Involuntary Movement Scale; MDD, major depressive disorder; ODT, orally dissolving tablet.